Suppr超能文献

碳酸钙和2.5毫当量/升钙透析液对矿物质代谢的长期影响。

Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism.

作者信息

Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J

机构信息

Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.

出版信息

Kidney Int. 1989 Nov;36(5):897-903. doi: 10.1038/ki.1989.277.

Abstract

Many investigators have shown that calcium carbonate (CaCO3) is an effective phosphate binder which also prevents the potential disabling effects of aluminum (Al) accumulation. However, hypercalcemia may develop in a substantial numbers of patients. Thus, to control serum phosphate (PO4) and prevent hypercalcemia, we performed studies in 21 patients on maintenance hemodialysis in which, in addition to the oral administration of CaCO3, the concentration of calcium (Ca) in the dialysate was reduced from 3.25 to 2.5 mEq/liter. The studies were divided in three periods: I. control, on Al-binders (one month); II. no Al-binders (one month); III. CaCO3 (seven months). Blood was obtained three times/week before dialysis for the first five months of the study and once a week for the remaining four months. During the control period, the mean serum calcium was 8.86 +/- 0.08 mg/dl. The value decreased to 8.65 +/- 0.07 mg/dl when phosphate binders containing aluminum were discontinued, and increased to 9.19 +/- 0.07 mg/dl (P less than 0.001 compared to period II) during oral supplementation with calcium carbonate. The mean serum phosphorus was 5.03 +/- 0.07 mg/dl during the control period, and increased to 7.29 +/- 0.91 mg/dl (P less than 0.001) after phosphate binders were discontinued. It decreased to 4.95 +/- 0.06 mg/dl (P less than 0.001) with the administration of calcium carbonate. During CaCO3 administration, serum Al decreased from 64.2 +/- 8.5 to 37.1 +/- 3.6 and 25.1 +/- 3.0 micrograms/liter (P less than 0.001) at three and seven months, respectively. Serum parathyroid hormone (PTH) decreased by 20%.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

许多研究者表明,碳酸钙(CaCO₃)是一种有效的磷结合剂,还能防止铝(Al)蓄积可能产生的致残效应。然而,相当多的患者可能会出现高钙血症。因此,为了控制血清磷(PO₄)并预防高钙血症,我们对21例维持性血液透析患者进行了研究,在研究中,除口服碳酸钙外,透析液中钙(Ca)的浓度从3.25毫当量/升降至2.5毫当量/升。研究分为三个阶段:I. 对照期,使用铝结合剂(1个月);II. 不使用铝结合剂(1个月);III. 使用碳酸钙(7个月)。在研究的前五个月,每周透析前采血3次,其余四个月每周采血1次。在对照期,血清钙平均值为8.86±0.08毫克/分升。停用含铝的磷结合剂后,该值降至8.65±0.07毫克/分升,在口服碳酸钙补充期间升至9.19±0.07毫克/分升(与第二阶段相比,P<0.001)。对照期血清磷平均值为5.03±0.07毫克/分升,停用磷结合剂后升至7.29±0.91毫克/分升(P<0.001)。服用碳酸钙后降至4.95±0.06毫克/分升(P<0.001)。在服用碳酸钙期间,血清铝在3个月和7个月时分别从64.2±8.5降至37.1±3.6和25.1±3.0微克/升(P<0.001)。血清甲状旁腺激素(PTH)下降了20%。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验